Manning & Napier Advisors LLC decreased its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 31.5% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 266,916 shares of the company's stock after selling 122,510 shares during the quarter. Manning & Napier Advisors LLC's holdings in Kenvue were worth $6,401,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently made changes to their positions in KVUE. SRS Capital Advisors Inc. raised its position in Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after purchasing an additional 571 shares in the last quarter. Clarity Asset Management Inc. acquired a new position in Kenvue in the fourth quarter worth about $45,000. SBI Securities Co. Ltd. acquired a new position in shares of Kenvue in the 4th quarter worth approximately $46,000. Deseret Mutual Benefit Administrators raised its holdings in shares of Kenvue by 29.0% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock worth $54,000 after buying an additional 568 shares in the last quarter. Finally, Versant Capital Management Inc raised its holdings in shares of Kenvue by 77.9% in the 1st quarter. Versant Capital Management Inc now owns 3,415 shares of the company's stock worth $82,000 after buying an additional 1,495 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Kenvue Price Performance
Shares of KVUE stock opened at $21.39 on Monday. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $25.17. The firm has a market capitalization of $41.03 billion, a price-to-earnings ratio of 38.88, a price-to-earnings-growth ratio of 3.32 and a beta of 0.98. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63. The firm has a fifty day moving average of $22.99 and a 200-day moving average of $22.40.
Kenvue (NYSE:KVUE - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The firm had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. During the same period in the previous year, the firm earned $0.28 earnings per share. The company's revenue was down 3.9% on a year-over-year basis. On average, equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were given a $0.205 dividend. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 annualized dividend and a dividend yield of 3.83%. Kenvue's dividend payout ratio is presently 149.09%.
Analysts Set New Price Targets
Several research analysts have issued reports on KVUE shares. Canaccord Genuity Group increased their price objective on Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Evercore ISI began coverage on shares of Kenvue in a research report on Monday, March 24th. They set an "in-line" rating and a $25.00 target price for the company. Citigroup reiterated a "neutral" rating on shares of Kenvue in a research report on Friday, June 13th. Piper Sandler raised their price objective on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. Finally, Redburn Atlantic initiated coverage on shares of Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective for the company. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Kenvue currently has an average rating of "Hold" and a consensus target price of $25.33.
Check Out Our Latest Report on KVUE
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
